TRAVERE THERAPEUTICS, INC. (TVTX) /
The cash flow of TRAVERE THERAPEUTICS, INC. over the past 10 years
Chart TRAVERE THERAPEUTICS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2023, TRAVERE THERAPEUTICS, INC.'s operating cash flow was -$280.02M and its capital expenditures $668K, leaving free cash flow of -$280.69M. Free cash flow was above zero in 1 of the 8 years shown. It ranged from -$280.69M in fiscal 2023 to $6.52M in fiscal 2017. Capital expenditures were highest in fiscal 2020, at $6.77M. No free cash flow figure is on file for fiscal 2024 and 2025.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $37.78M | — | — |
| 2024ended Dec 31, 2024 | -$237.47M | — | — |
| 2023ended Dec 31, 2023 | -$280.02M | $668K | -$280.69M |
| 2022ended Dec 31, 2022 | -$186.29M | $191K | -$186.48M |
| 2021ended Dec 31, 2021 | -$14.79M | $5.1M | -$19.89M |
| 2020ended Dec 31, 2020 | -$42.74M | $6.77M | -$49.51M |
| 2019ended Dec 31, 2019 | -$58.21M | $195K | -$58.41M |
| 2018ended Dec 31, 2018 | -$24.96M | $727K | -$25.68M |
| 2017ended Dec 31, 2017 | $7.4M | $887K | $6.52M |
| 2016ended Dec 31, 2016 | -$3.44M | $1.43M | -$4.87M |
Fiscal years as TRAVERE THERAPEUTICS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on TRAVERE THERAPEUTICS, INC.
- The revenue of TRAVERE THERAPEUTICS, INC.
- The profitability of TRAVERE THERAPEUTICS, INC.
- The debt of TRAVERE THERAPEUTICS, INC.
- All of TRAVERE THERAPEUTICS, INC.'s financials, charted
Companies of a similar size
Not investment advice. This page shows what TRAVERE THERAPEUTICS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.